Kyle Faget Authors Article on Considerations for Mobile Health Technology Developers
September 28, 2022
pharmaphorum
Foley & Lardner LLP Partner Kyle Faget authored the article, “Considerations for Mobile Health Technology Developers: Part 1,” published by pharmaphorum, about the U.S. Food and Drug Administration (FDA)’s common approach to regulating mHealth products, general wellness devices, and mobile medical applications.
Faget says, “Although mHealth has been gaining in popularity for at least the past decade, before commercializing their mHealth products, developers must determine whether the product is subject to (FDA) regulation as a medical device. If so, developers must develop and execute on a regulatory strategy.”
Part 2 of this series will be devoted to clinical decision support (CDS) software.
Related News
June 22, 2026
In the News
Aaron Maguregui Authors Article on Building Scalable, Secure AI Strategies
Foley & Lardner LLP partner Aaron Maguregui authored the HealthTech article, “A Digital Health CEO’s Guide to Fast, Secure Scaling of AI,” offering guidance to digital health leaders on artificial intelligence scaling.
June 5, 2026
In the News
Jeffrey Blease Featured Across the Media for Litigation Department Chair Appointment
Foley & Lardner LLP partner Jeffrey Blease is featured across legal media for his recent appointment as chair of the firm's national litigation department.
June 5, 2026
In the News
David Rosen Discusses SCOTUS Ruling on Generic Drug Labeling
Foley & Lardner LLP partner David Rosen is quoted across the media for his analysis of the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.